Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE008 (KOR) (Dr. Kim)
· consented 2023-01-25
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 211); relationship: not assessed; serious criteria: hospitalization
severe
serious
assessed
2026-08-18
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-10 (study day 277); relationship: not assessed; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 363); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-12 (study day 371); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-05-07 (study day 456); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.